Home
Search
Intellectual Property

Patents

The value of patents to biotechnology innovation cannot be understated. They enable innovators time to recoup the massive development costs of a new biotech product. Strong intellectual property measures are necessary to advance biotechnology innovation, the creation of high-wage, high-value jobs, and the ability to bring life-saving treatments and cures to market.

BIO Toolkit Resources
innovation-drug
Patents Drive Innovation of both New and Improved Products

In the public debate over drug costs, there is a lot of discussion about so-called “evergreening.” 

Learn More
drugs
Hatch-Waxman: Carefully Balancing the Need for Innovation and Drug Competition
Learn More
patented
Strong Patents Drive Innovation
Learn More
Foreign Pricing
H.R. 3 Imports Risky Foreign Pricing Schemes
Learn More
BIO Comments on Patent Policy
Amicus Briefs
Browse all Amicus Briefs
BIO Files Amicus Brief in Petition for a Writ of Certiorari in American Axle & Manufacturing, Inc., v. Neapco Holdings LLC, et al., at the Supreme Court of the United States.
June 29, 2021
BIO and AUTM have filed an amicus brief in petition for a writ of certiorari the in American Axle & Manufacturing, Inc., v. Neapco Holdings LLC, et al., at the Supreme Court of the United States. BIO and AUTM are concerned that the Federal Circuit is misapplying the Supreme Court…
BIO FILES AMICUS BRIEF CHALLENGING FTC’S OVERREACH ON MERGER ENFORCEMENT THAT THREATENS DRUG DEVELOPMENT INNOVATION
August 24, 2023
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen. The amicus brief was filed in the U.S. District Court, Northern District of Illinois, Eastern Division.  In…
BIO Files Amicus Brief in U.S. ex rel. Scutte v. SuperValu Inc. at the Supreme Court of the United States
March 28, 2023
BIO has filed an amicus brief in U.S. ex rel. Scutte v. SuperValu Inc., which addresses the issue of the intent requirement under the False Claims Act (FCA). Specifically, BIO urges the Court to uphold the view that a firm does not have the requisite intent to violate the FCA when…
Letters, Comments & Testimony
Browse all Letters, Comments & Testimony
BIO Submits Comments to the USPTO on Discretion to Institute Trials Before the Patent Trial and Appeal Board
August 6, 2021
BIO submitted comments to the United States Patent and Trademark Office in response to the USPTO's consideration of “the codification of its current policies and practices, or the modification thereof,” relating to the exercise of its discretion under 35 U.S.C. §§ 314(a), 324(a), 315(d), and 325(d)…
BIO Comments on Proposed NIST Rule
April 9, 2021
The Biotechnology Innovation Organization (BIO) submitted the below comments to the National Institute of Standards and Technology on proposed revisions to regulations that would further the Return on Investment (ROI) Initiative for Unleashing American Innovation.
BIO's 2021 Special 301 Submission
January 28, 2021
Section 182 of the Trade Act of 1974, known as the “Special 301” provisions, requires the United States Trade Representative to identify countries that deny adequate and effective intellectual property protections or fair and equitable market access to U.S. persons who rely on IP protection. As…
Become an Advocate for Biotechnology
Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.

Join BIOAction